'Company Statement: Investigational SAGE-718 Granted Nonproprietary Name of Dalzanemdor' - Sage Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Sage Therapeutics announced that its investigational drug SAGE-718 has been granted the nonproprietary name 'Dalzanemdor'. This is a key step in the drug development process, indicating progress towards potential commercialization. The new name will be used in clinical trials and future marketing.
December 05, 2023 | 2:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sage Therapeutics' SAGE-718, now named 'Dalzanemdor', has reached a milestone in its development process, which may positively influence investor perception and the company's valuation in the short term.
The granting of a nonproprietary name to SAGE-718, now Dalzanemdor, is a positive regulatory development, often perceived by investors as a sign of progress in the drug's path to market. This can lead to increased investor confidence and a potential short-term uptick in SAGE's stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100